World Kidney Day 2026 | What Sponsors Should Know About the Future of Kidney Trials
As World Kidney Day 2026 is marked around the world, kidney disease is increasingly moving to the forefront of global healthcare discussions.
More than 850 million people worldwide live with some form of kidney disease, roughly twice the number of people living with diabetes (422 million) and nearly 20 times more than the global prevalence of cancer (53,5 million) or HIV/AIDS (36.7 million).
Despite this enormous disease burden, nephrology has historically received far less attention in drug development compared with therapeutic areas such as oncology or rare diseases. That dynamic is now beginning to change.
Over the past few years, growing cardio-renal research, new regulatory momentum, and expanding pipelines in areas such as IgA nephropathy and rare kidney diseases have started to reshape the clinical trial landscape.
On World Kidney Day, here are several trends sponsors should watch.
Nephrology Is Gaining Momentum: Emerging Kidney Disease Pipelines
Chronic kidney disease is projected to become the 5th leading cause of years of life lost globally by 2040, highlighting the growing urgency around kidney health. Policy and clinical evidence are also accelerating interest in this space. The World Health Assembly recently adopted its first resolution focused on kidney health (WHA78.6), recognizing kidney disease prevention and treatment as part of the broader global strategy on non communicable diseases.
The kidney drug development pipeline is expanding rapidly and can broadly be viewed in two directions. The first focuses on large cardio-renal-metabolic populations, where outcomes trials can support broad regulatory labels and strong value propositions for payers. A key example is the FLOW trial, which showed that semaglutide reduced major kidney outcomes and cardiovascular death in patients with type 2 diabetes and chronic kidney disease.
The second direction targets specific kidney diseases driven by immune or complement pathways. In these indications, biomarkers such as proteinuria are increasingly used to accelerate development timelines, although confirmatory trials remain essential.
Several recent approvals highlight this growing momentum. In IgA nephropathy, therapies such as sparsentan and atrasentan have received FDA approvals or accelerated approvals based on strong clinical data. Complement-targeting therapies are also advancing. For example, iptacopan received FDA approval in 2025 for C3 glomerulopathy, a rare but severe kidney disease.
Overall, multiple kidney medicines received regulatory approvals in 2025 across CKD, C3G, and lupus nephritis, reflecting growing investment and innovation in nephrology.
The Biggest Challenges in Kidney Trials
Despite growing investment in nephrology, kidney trials remain complex to design and execute.
One major challenge is endpoint strategy. In diseases such as IgA nephropathy, accelerated approvals are increasingly based on proteinuria reduction as a surrogate endpoint. However, regulators require confirmatory trials to demonstrate long-term slowing of kidney function decline before full clinical benefit is established.
Another challenge is underdiagnosis of chronic kidney disease. According to the CDC, most adults with CKD are unaware they have the condition, which can significantly limit the pool of patients available for clinical trials.
Operational complexity is also increasing as kidney trials expand globally. Differences in background care, diagnostic practices, and laboratory measurements can introduce variability that affects trial outcomes.
Finally, some newer therapies bring additional safety and monitoring requirements, such as vaccination protocols or enhanced safety monitoring, which must be carefully integrated into trial design and site operations.
Opportunities for sponsors
The opportunity in 2026 is less about “doing more kidney trials” and more about de‑risking and accelerating decision‑quality: maximizing time‑to‑signal without mortgaging confirmatory credibility.
Key Opportunity | What It Means for Sponsors |
Plan accelerated and confirmatory evidence together | If a program uses surrogate endpoints such as proteinuria for accelerated approval, confirmatory trials demonstrating long term kidney benefit should be planned from the start. |
Account for evolving standard of care | New clinical guidelines and cardio renal therapies are raising the baseline of treatment. Trials should carefully document background therapy to ensure clear treatment effects. |
Make patient identification a core strategy | Many patients with CKD remain undiagnosed. Recruitment often depends more on referral networks and pre screening programs than simply increasing the number of trial sites. |
Integrate safety requirements early | Some kidney therapies require vaccination protocols, safety monitoring, or reproductive risk controls. These operational steps should be integrated into trial planning and site preparation. |
Align trials with policy and public health priorities | Growing global focus on kidney health and prevention can support stronger evidence generation strategies and future market access discussions. |
The Role of Experienced CRO Partners
Kidney clinical trials can be particularly challenging to run. Study success often depends on careful endpoint management, consistent laboratory measurements such as proteinuria and eGFR, and accurate diagnosis, especially in rare kidney diseases.
Operational planning is also critical. Recruitment, safety monitoring, and patient retention all need to be carefully coordinated to avoid delays and ensure reliable data.
This is where an experienced CRO partner can make a real difference. Strong CRO teams help sponsors design realistic recruitment strategies, select appropriate sites, and standardize key processes such as background therapy and endpoint measurement.
At Cromos Pharma, we support sponsors with integrated clinical research services across all trial phases, including study design, regulatory support, site management, patient recruitment, and data management. Our teams combine medical expertise with operational experience to help sponsors navigate complex therapeutic areas such as nephrology and bring new treatments to patients more efficiently.
As interest in kidney disease research continues to grow, collaboration between sponsors, investigators, and experienced CRO partners will play a key role in accelerating the development of new therapies.
